Skip to main content
. Author manuscript; available in PMC: 2018 Aug 1.
Published in final edited form as: Nanomedicine. 2017 Apr 17;13(6):1925–1932. doi: 10.1016/j.nano.2017.04.004

Figure 5. Targeting of nanogel loaded Rhodamine to the bladder.

Figure 5

A) Synthesis of nanogel, CGKRK-nanogel and CGKRK-nanogel Rhodamine B. Full description of the synthesis is in Methods section; B) Release profile of Rhodamine B from plain nanogel and CGKRK-nanogel. CGKRK-nanogel shows a slightly slower release rate than plain nanogel, likely due to additional mesh that delays the exit of the rhodamine from the nanogel. The difference was not statistically significant. C) Administration of CGKRK-nanogel (without Rhodamine B) to the focally injured bladder results in FITC fluorescence accumulation (arrow); D) Administration of Rhodamine B-loaded nanogel to the focally injured bladder results in Rhodamine B fluorescence for CGKRK-nanogel Rhodamine (left), but not for non-targeted nanogel Rhodamine B (right). FITC fluorescence is not shown due to an overwhelming bleed through of Rhodamine B into the FITC channel; E) quantification of Rhodamine B fluorescence shows significantly higher accumulation for the CGKRK-nanogel Rhodamine B (n=5 for targeted nanogel, n=6 for non-targeted nanogel Rhodamine B, n=2 for CGKRK-nanogel (empty), p-value 0.0049, parametric 2-sided t-test); F) histological sections of the nanogel-treated bladders show widespread accumulation of Rhodamine fluorescence in the bladder treated with CGKRK-nanogel Rhodamine B but not in the bladder treated with nanogel Rhodamine B.